Recording two-digit growth since its inception, Horus Pharma ended the year 2019 with a turnover of 64 million€. A good progress which is expected to continue with a forecast turnover over 75 million € In 2020.
With the launch of its firts european subsidiaries and supported by a growing network of international distributors, the Group expects to achieve 50% of its turnover from exports within the next 3 to 5 years. 10% of sales invested in R&D to gradually reach 15% over the next five years.
In the span of 4 years between 2013 and 2017, the number of Horus Pharma employees has doubled growing to nearly 150 employees today.
At the rate of 3 to 4 new product launches per year, the laboratory's product portfolio has expanded to bring together some fifty specialties.
The position Horus Pharma holds in the National Ranking for SMEs and most successful independent French ETI